CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Leap Therapeutics, Inc. - LPTX CFD

    2.68
    3.94%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 2.79
    Open* 2.74
    1-Year Change* 495.65%
    Day's Range* 2.68 - 2.83
    52 wk Range 1.24-10.20
    Average Volume (10 days) 270.33K
    Average Volume (3 months) 5.40M
    Market Cap 62.38M
    P/E Ratio -100.00K
    Shares Outstanding 25.57M
    Revenue N/A
    EPS -5.72
    Dividend (Yield %) N/A
    Beta 0.69
    Next Earnings Date Mar 22, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 2.68 -0.06 -2.19% 2.74 2.83 2.68
    Dec 7, 2023 2.79 0.04 1.45% 2.75 2.86 2.73
    Dec 6, 2023 2.75 0.09 3.38% 2.66 2.88 2.57
    Dec 5, 2023 2.68 0.06 2.29% 2.62 2.79 2.49
    Dec 4, 2023 2.59 0.32 14.10% 2.27 2.61 2.27
    Dec 1, 2023 2.27 0.13 6.07% 2.14 2.34 2.11
    Nov 30, 2023 2.21 -0.29 -11.60% 2.50 2.53 2.08
    Nov 29, 2023 2.46 0.00 0.00% 2.46 2.56 2.39
    Nov 28, 2023 2.42 -0.06 -2.42% 2.48 2.49 2.38
    Nov 27, 2023 2.56 0.03 1.19% 2.53 2.56 2.13
    Nov 24, 2023 2.40 -0.40 -14.29% 2.80 2.85 2.32
    Nov 22, 2023 2.81 0.39 16.12% 2.42 2.99 2.42
    Nov 21, 2023 2.39 0.26 12.21% 2.13 2.49 2.13
    Nov 20, 2023 2.02 0.21 11.60% 1.81 2.19 1.78
    Nov 17, 2023 1.80 0.26 16.88% 1.54 1.83 1.54
    Nov 16, 2023 1.54 0.01 0.65% 1.53 1.54 1.37
    Nov 15, 2023 1.55 0.01 0.65% 1.54 1.63 1.53
    Nov 14, 2023 1.47 0.00 0.00% 1.47 1.54 1.43
    Nov 13, 2023 1.41 0.02 1.44% 1.39 1.48 1.30
    Nov 10, 2023 1.33 -0.03 -2.21% 1.36 1.43 1.31

    Leap Therapeutics, Inc. Events

    Time (UTC) Country Event
    Friday, March 22, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 Leap Therapeutics Inc Earnings Release
    Q4 2023 Leap Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 1.5 1.5 0 0
    Revenue 0 1.5 1.5
    Total Operating Expense 56.763 42.926 30.039 33.451 30.751
    Selling/General/Admin. Expenses, Total 11.798 10.766 9.616 9.085 8.921
    Research & Development 44.965 32.16 20.423 24.366 21.83
    Operating Income -56.763 -41.426 -28.539 -33.451 -30.751
    Interest Income (Expense), Net Non-Operating 0.263 -0.411 0.792 0.416 6.877
    Other, Net 2.051 1.226 0.231 0.132 0.756
    Net Income Before Taxes -54.449 -40.611 -27.516 -32.903 -23.118
    Net Income After Taxes -54.596 -40.587 -27.514 -32.9 -23.138
    Net Income Before Extra. Items -54.596 -40.587 -27.514 -32.9 -23.138
    Net Income -54.596 -40.587 -27.514 -32.9 -23.138
    Income Available to Common Excl. Extra. Items -54.596 -40.587 -37.588 -33.259 -23.138
    Income Available to Common Incl. Extra. Items -54.596 -40.587 -37.588 -33.259 -23.138
    Diluted Net Income -54.596 -40.587 -37.588 -33.259 -23.138
    Diluted Weighted Average Shares 11.3239 8.58253 5.93277 2.25827 1.41443
    Diluted EPS Excluding Extraordinary Items -4.8213 -4.72903 -6.33566 -14.7276 -16.3585
    Diluted Normalized EPS -4.8213 -4.72903 -6.33566 -14.7276 -16.3585
    Total Extraordinary Items
    Total Adjustments to Net Income 0 -10.074 -0.359 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0
    Total Operating Expense 14.662 42.726 13.943 15.288 16.9
    Selling/General/Admin. Expenses, Total 3.558 3.784 2.909 3.186 2.855
    Research & Development 11.104 9.36 11.034 12.102 14.045
    Operating Income -14.662 -42.726 -13.943 -15.288 -16.9
    Interest Income (Expense), Net Non-Operating 0.974 0.591 1.213 -0.458 -0.711
    Other, Net 0.298 0.272 0.775 0.652 0.587
    Net Income Before Taxes -13.39 -41.863 -11.955 -15.094 -17.024
    Net Income After Taxes -13.39 -41.863 -12.102 -15.094 -17.024
    Net Income Before Extra. Items -13.39 -41.863 -12.102 -15.094 -17.024
    Net Income -13.39 -41.863 -12.102 -15.094 -17.024
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -13.39 -41.863 -12.102 -15.094 -17.024
    Income Available to Common Incl. Extra. Items -13.39 -41.863 -12.102 -15.094 -17.024
    Diluted Net Income -13.39 -41.863 -12.102 -15.094 -17.024
    Diluted Weighted Average Shares 14.7104 12.9344 11.3239 11.3239 8.83185
    Diluted EPS Excluding Extraordinary Items -0.91024 -3.23656 -1.06871 -1.33293 -1.92757
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.91024 -0.94948 -1.06871 -1.33293 -1.92757
    Unusual Expense (Income) 29.582
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 67.95 116.874 52.274 4.241 17.322
    Cash and Short Term Investments 65.5 114.916 52.071 3.891 16.284
    Cash & Equivalents 65.5 114.916 52.071 3.891 16.284
    Total Receivables, Net 2.099 1.189 0.073 0.185 0.836
    Prepaid Expenses 0.351 0.769 0.13 0.165 0.202
    Other Current Assets, Total
    Total Assets 70.353 117.911 54.371 7.448 19.074
    Property/Plant/Equipment, Total - Net 0.689 0.495 0.593 1.15 0.086
    Property/Plant/Equipment, Total - Gross 0.895 0.685 0.754 1.289 0.208
    Accumulated Depreciation, Total -0.206 -0.19 -0.161 -0.139 -0.122
    Other Long Term Assets, Total 1.714 0.542 1.504 2.057 1.666
    Total Current Liabilities 11.225 9.987 7.372 8.486 6.451
    Accounts Payable 5.657 4.189 2.717 4.571 3.579
    Accrued Expenses 5.568 5.798 3.155 3.915 2.872
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 11.487 10.024 7.72 9.197 9.899
    Total Long Term Debt 0 0 0 0 0
    Total Equity 58.866 107.887 46.651 -1.749 9.175
    Redeemable Preferred Stock
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.099 0.088 0.06 0.024 0.015
    Additional Paid-In Capital 376.807 371.638 270.155 193.319 162.393
    Retained Earnings (Accumulated Deficit) -318.168 -263.572 -222.985 -195.168 -153.535
    Other Equity, Total 0.128 -0.267 -0.579 0.076 0.302
    Total Liabilities & Shareholders’ Equity 70.353 117.911 54.371 7.448 19.074
    Total Common Shares Outstanding 9.90214 8.83185 5.96577 2.41949 1.47032
    Other Liabilities, Total 0.262 0.037 0.348 0.711 3.448
    Other Current Liabilities, Total 0 1.5
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 81.761 93.88 104.699 67.95 79.938
    Cash and Short Term Investments 80.743 91.415 102.038 65.5 78.308
    Cash & Equivalents 80.743 91.415 102.038 65.5 78.308
    Total Receivables, Net 0.753 2.046 2.071 2.099 1.256
    Prepaid Expenses 0.265 0.419 0.59 0.351 0.374
    Total Assets 83.046 95.857 106.547 70.353 82.165
    Property/Plant/Equipment, Total - Net 0.372 0.48 0.585 0.689 0.791
    Note Receivable - Long Term 0.563 0.272
    Other Long Term Assets, Total 0.913 0.934 0.991 1.714 1.436
    Total Current Liabilities 11.038 11.762 10.311 11.225 11.723
    Accounts Payable 5.899 6.5 5.498 5.657 6.276
    Accrued Expenses 5.139 5.262 4.813 5.568 5.447
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total
    Total Liabilities 11.038 11.8 10.503 11.487 12.092
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0 0.038 0.192 0.262 0.369
    Total Equity 72.008 84.057 96.044 58.866 70.073
    Common Stock 0.026 0.026 0.119 0.099 0.099
    Additional Paid-In Capital 458.339 457.038 387.886 376.807 375.35
    Retained Earnings (Accumulated Deficit) -387.117 -373.421 -360.031 -318.168 -306.066
    Other Equity, Total 0.76 0.414 0.355 0.128 0.69
    Total Liabilities & Shareholders’ Equity 83.046 95.857 106.547 70.353 82.165
    Total Common Shares Outstanding 25.5654 25.5654 11.9411 9.90214 9.90214
    Redeemable Preferred Stock 67.715
    Total Preferred Shares Outstanding 119.411
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -54.596 -40.587 -27.514 -32.9 -23.138
    Cash From Operating Activities -49.044 -35.157 -25.957 -26.902 -26.033
    Cash From Operating Activities 0.016 0.029 0.034 0.047 0.049
    Non-Cash Items 6.187 4.388 2.243 4.62 -3.815
    Changes in Working Capital -0.803 1.002 -0.684 1.334 0.851
    Cash From Investing Activities 0 0.025 -0.085 0
    Capital Expenditures 0 -0.1 0
    Cash From Financing Activities -0.21 98.035 73.997 14.817 15.906
    Financing Cash Flow Items -0.21 -0.184 -1.906 1.486 -0.359
    Issuance (Retirement) of Stock, Net 0 98.219 75.903 13.331 16.265
    Issuance (Retirement) of Debt, Net 0
    Foreign Exchange Effects -0.162 -0.033 0.115 -0.223 0.674
    Net Change in Cash -49.416 62.845 48.18 -12.393 -9.453
    Deferred Taxes 0.152 0.011 -0.036 -0.003 0.02
    Other Investing Cash Flow Items, Total 0 0.025 0.015
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -41.863 -54.596 -42.494 -27.4 -10.376
    Cash From Operating Activities -12.7 -49.044 -36.03 -23.777 -11.518
    Cash From Operating Activities 0.004 0.016 0.012 0.008 0.004
    Non-Cash Items 31.249 6.187 5.33 3.174 1.073
    Changes in Working Capital -2.09 -0.803 1.122 0.441 -2.219
    Cash From Financing Activities -0.029 -0.21 -0.21 -0.21 -0.21
    Financing Cash Flow Items 0 -0.21 -0.21 -0.21 -0.21
    Issuance (Retirement) of Stock, Net -0.029 0 0 0
    Foreign Exchange Effects -0.05 -0.162 -0.368 -0.046 0.032
    Net Change in Cash 36.538 -49.416 -36.608 -24.033 -11.696
    Deferred Taxes 0.152
    Cash From Investing Activities 49.317
    Other Investing Cash Flow Items, Total 49.317
    Capital Expenditures

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Leap Therapeutics, Inc. Company profile

    About Leap Therapeutics Inc

    Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models. TRX518 is a humanized anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody designed for the immune system’s anti-tumor response as an immune checkpoint agonist.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Leap Therapeutics Inc revenues remained flat at $1.5M. Net loss applicable to common stockholders increased 8% to $40.6M. Revenues reflect market conditions. Higher net loss reflects Research and development - Balancing va increase of 57% to $30.5M (expense), Foreign currency gains (losses) decrease from $738K (income) to $379K (expense).

    Industry: Bio Therapeutic Drugs

    47 Thorndike St Ste B1-1
    CAMBRIDGE
    MASSACHUSETTS 02142-1799
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    BTC/USD

    44,047.25 Price
    -1.270% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    XRP/USD

    0.68 Price
    +0.260% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading